PT - JOURNAL ARTICLE AU - TAKURO OKADA AU - ISAKU OKAMOTO AU - HIROKI SATO AU - TATSUYA ITO AU - KEITARO MIYAKE AU - KIYOAKI TSUKAHARA TI - Efficacy and Safety of Paclitaxel Combined With Cetuximab for Head and Neck Squamous Cell Carcinoma AID - 10.21873/invivo.12376 DP - 2021 Mar 01 TA - In Vivo PG - 1253--1259 VI - 35 IP - 2 4099 - http://iv.iiarjournals.org/content/35/2/1253.short 4100 - http://iv.iiarjournals.org/content/35/2/1253.full SO - In Vivo2021 Mar 01; 35 AB - Background/Aim: For recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN), popular regimens containing platinum-based anticancer agents and immune checkpoint inhibitors are impractical for platinum-intolerant patients. Herein, the efficacy and safety of paclitaxel and cetuximab combination therapy in R/M SCCHN were evaluated. Patients and Methods: In this retrospective study, paclitaxel (80 mg/m2) and cetuximab (400 mg/m2 loading dose followed by 250 mg/m2 weekly) were administered in 28-day cycles on days 1, 8, and 15. Results: Thirty-eight patients were treated. The overall response and disease control rates of first-line therapy were 43% and 79%, respectively, while those of second-line and later therapies were 20% and 90%, respectively. The median progression-free and overall survival were 5.3 and 12.5 months, respectively. All adverse events were manageable, including grade 3/4 neutropenia and anaemia affecting 8-13% of patients. Conclusion: Paclitaxel and cetuximab combination therapy may be suitable for treating R/M SCCHN.